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Background: Bronchopulmonary dysplasia (BPD) in premature infants is a predominantly secondary occurrence to
intrauterine inflammation/infection and postpartum mechanical ventilation; in recent years, an association with
epigenetics has also been found. DNA methylation, catalyzed by DNA methyl transferases (DNMTs), and tri-methylation
of lysine 27 on histone H3 (H3K27me3), mediated by the methyltransferase, Enhancer of Zeste Homolog 2 (EZH2),
are some of the most commonly found modifications in epigenetics. Runt-related transcription factor 3 (RUNX3) is
associated with pulmonary epithelial and vascular development and regulates expression at the post-transcriptional
level by DNA methylation through DNMT1 or DNMT3b. However, the involvements of these epigenetic factors in the
occurrence of BPD are, as yet, unclear.
Methods: Newborn rats were randomly assigned to a model, hyperoxia (85 % O2) or control, normoxia group
(21 % O2). Lung tissues and alveolar type 2 (AT2) epithelial cells were collected between 1–14 days. The expression
of DNMTs, and EZH2 was detected by immunohistochemistry, Western blot and real-time PCR. The percentage of
DNA methylation and H3K27me3 levels in the RUNX3 promoter region was measured by bisulfite sequencing PCR
and chromatin immunoprecipitation assay. RUNX3 protein and mRNA expression in AT2 cells was also measured
after inhibition using the DNA methylation inhibitor, 5-Aza-2′-deoxycytidine, the H3K27me3 inhibitor, JMJD3, and
the EZH2 inhibitor, DZNep.
Results: Compared with the control group, RUNX3 protein was downregulated and DNMT3b and EZH2 were
highly expressed in lung tissues and AT2 cells of the model group (P < 0.05), while high DNA methylation and
H3K27me3 modifications were present in the RUNX3 promoter region, in lung tissues of the model group (P < 0.05).
Following hyperoxia in the model group, JMJD3 and DZNep significantly reversed the hyperoxia-induced
down-regulation of RUNX3 expression in AT2 cells (P < 0.05), more so than 5-Aza-2′-deoxycytidine (P < 0.05).
Conclusions: 1) DNA methylation and H3K27 trimethylation are present in the BPD model; 2) RUNX3 down-regulation
is attributed to both DNMT3b-catalyzed DNA methylation and EZH2-catalyzed histone methylation.
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Bronchopulmonary dysplasia (BPD) is a common, chronic
lung disease of infants, frequently seen in premature
newborns with a fetal age < 30 weeks and a birth weight
< 1,500 g. The occurrence of BPD is mostly secondary
to intrauterine inflammation/infection or postpartum
mechanical ventilation, oxygen support, and changes
in other environmental factors. The main pathological
changes that characterize BPD are alveolar structure
simplification and pulmonary capillary dysplasia [1]. In
recent years, a large number of studies have revealed
that some genes, including those for vascular endothe-
lial growth factor (VEGF) [2], interleukin 1-beta (IL-1β)
[3] and mucin 1 (MUC1) [4], participate in the pul-
monary developmental disorder process of BPD by
regulating alveolar formation.
Runt-related transcription factor 3 (RUNX3) is a
member of the RUNX family and participates in normal
physiological, as well as pathological, processes of the
immune system [5], in tumor formation [6] and in other
disorders. RUNX3 is also associated with pulmonary
epithelial and vascular development [7]. Previous studies
have shown that RUNX3 was expressed in mouse
pulmonary epithelium at E15.5 [8], while RUNX3
knock-out caused pulmonary epithelial hyperplasia [8]
and pulmonary vascularization disorder [7], similar to
the pathological changes seen in BPD [1]. RUNX3 often
regulates expression at the post-transcriptional level by
DNA methylation [9]. However, the mechanisms be-
hind RUNX3 down-regulation and any potential regu-
lators of abnormal RUNX3 expression in a BPD model
have, as yet, to be defined.
The silencing of RUNX3 expression is associated
with the tri-methylation of lysine 27 on histone H3
(H3K27me3), an epigenetic marker, and is mediated by
the methyltransferase, Enhancer of Zeste Homolog 2
(EZH2) [10, 11] and demethyltransferase, JMJD3/UTX
[12], to reduce transcription [13]. Fujii et al. [14] found that
EZH2 knock-out reduced H3K27me3-binding RUNX3
levels and thus up-regulated RUNX3 mRNA levels.
DNA methyl transferases (DNMTs) catalyze DNA
methylation, which leads to the silencing of gene expres-
sion. Common DNMTs include DNMT1, which main-
tains and regulates DNA methylation, and DNMT3a/b,
which establishes de novo methylation [15, 16]. DNMT1
was thought to be the major contributor of RUNX3
DNA methylation, but DNMT3b has also been found to
have a role [17]. Additionally, Deng et al. [10] found
that the inhibition of DNMT3b expression caused the
upregulation of RUNX3 expression in a colorectal
cancer cell line.
Numerous studies have suggested that BPD is a genet-
ically susceptible disease. Studies of twins have shown that
the BPD status of one twin was a significant predictor ofBPD in the second twin [18], and that the incidence of
BPD in homozygotic twins was significantly greater
than that of dizygotic twins [19]. Subsequently, many
scholars have reported abnormalities of histone acety-
lase activity and the chromatin remodeling pathway in
BPD patients, and believe that epigenetics is a causal fac-
tor in the occurrence and development of BPD [20–23].
However, whether two common epigenetic modifications–
DNA methylation and H3K27me3–are associated with
BPD [24], and whether, by regulating target genes, they
participate in the pulmonary developmental disorder
processes of BPD is unclear. Consequently, this study
aimed to identify the presence or absence of DNA
methylation and H3K27me3 in BPD, and to highlight
any correlation between RUNX3 down-regulation and
DNA methylation or H3K27me3 in BPD at the epigen-
etic level.
Experimental methods
Animal model and tissue specimens
A newborn rat model of BPD, established by our re-
search group as previously described, was used [25].
Two hundred newborn, Sprague–Dawley (SD) rats were
randomly divided into a model (exposure to hyperoxia
[85 % O2] from day of birth) or control group (exposure
to normoxia [21 % O2]). To avoid O2 toxicity, maternal
rats within the model and control groups were switched
once every 24 h. Rats were given ad libitum access to
water and food. At 1, 7, 10 and 14 days after the start of
exposure to hyperoxia or normoxia, eight newborn rats
from each model or control group were anesthetized by
intraperitoneal injection with 5 % chloral hydrate, and
whole lungs collected aseptically by chest opening. The
left lungs were fixed in paraformaldehyde (PFA) for sub-
sequent immunohistochemical staining, the right upper
lung lobes were used for real-time PCR analysis, and the
right lower lung lobes for Western blots. All specimens
were snap-frozen in liquid nitrogen and stored at −80 °C
until use. Mature SD rats with a body weight of 220–250 g
were purchased from the Department of Animals,
Experimental Center, Shengjing Hospital of China Medical
University (Shenyang, China). All animal experiments
were approved and supervised by the Ethics Committee of
Animals, China Medical University.
AT2 cell isolation and purification
The above BPD animal model was employed. At 0, 1, 7,
10 and 14 days after the start of normoxia or hyperoxia,
alveolar type 2 (AT2) epithelial cells of newborn rats were
isolated from the control or model groups, respectively,
for primary culture. As previously described [26, 27],
tracheal intubation was performed on anesthetized rats
to maintain lung ventilation and to conduct the subse-
quent lavage. Two cold buffer solutions and an albumin
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cannula lavage to remove blood and macrophages from
lung tissues. AT2 cells were isolated by mechanical
separation and trypsinization of lung tissue, followed by
filtration with a nylon mesh. A first-round purification
was conducted based on differential cell adherence, and
a second-round purification was performed using a
lamellar body cell membrane antibody p180 (Abcam,
Cambridge, MA, USA). After storage in liquid nitrogen,
AT2 cells of the model and control groups, isolated at
1, 7, 10 and 14 days, were transferred to a −80 °C
freezer and then subsequently used for real-time PCR,
Western blot, bisulfite sequencing PCR (BSP) analysis and
chromatin immunoprecipitation (ChIP) assay. Purified
AT2 cells, extracted immediately after birth (0 day), were
used for inhibitor treatments as described below.
Cell treatment
Purified AT2 cells extracted immediately after birth (0 day)
were plated out into 6-well plates and then cultured in
environments of differing oxygen concentrations: a con-
trol (21 % O2) or model (85 % O2) group. Each group of
cells was cultured in the presence of various concentra-
tions of 5-Aza-2′-deoxycytidine (5-Aza-CdR, Abcam; 2.5, 5
or 10 μmol/L), Jumonji domain containing 3 (Jmjd3,
Abcam; 10, 20 or 40 μg/L) or 3-Deazaneplanocin A
(DZNep, Selleckchem, Shanghai, China; 1, 2.5 or 5 μmol/L)
for 48 h, or treated with 5 μmol/L 5-Aza-CdR, 20 μg/L
Jmjd3 or 1 μmol/L DZNep for 24, 48 or 72 h. Inhibitors
and media were changed every 24 h until cells were
collected. Cells of the negative control and model
groups were cultured without inhibitors. After storage
in liquid nitrogen, cells were transferred to a −80 °C
freezer and then subsequently used for real-time PCR
and Western blotting.
Immunohistochemistry
PFA-fixed lung tissues were dehydrated, vitrified, embed-
ded in paraffin, fixed and cut into 4 μm-thick sections,
which were then fixed in a 60 °C oven for 4 h. Sections
were dewaxed with dimethyl benzene, hydrated with
gradient alcohol according to manufacturer’s instruc-
tions (immunohistochemistry kit; MXB, Fujian, China),
and treated with 3 % H2O2 to block endogenous perox-
idase activity. Treated sections were placed into an
EDTA-Tris buffer solution and microwaved for 20 min,
blocked with serum, and incubated overnight at 4 °C
with various antibodies: rabbit polyclonal anti-RUNX3,
1:200 (Abcam); rabbit polyclonal anti-DNA methyltrans-
ferase 3b, 1:500 (DNMT3b, Abcam); mouse monoclonal
anti-H3K27me3, 1:1000 (Abcam); rabbit polyclonal anti-
DNA methyltransferase 1, 1:50 (DNMT1; Santa Cruz
Biotechnology, Dallas, TX, USA); or mouse monoclonal
anti-Enhancer of Zeste Homolog 2, 1:200 (EZH2; Becton,Dickinson and Co, Franklin Lakes, NJ, USA). After
sequential incubation with biotin-labeled secondary
antibodies and streptavidin-peroxidase, sections were
developed with 3,3′-diaminobenzidine (DAB), dehy-
drated and mounted. A laser scanning confocal micro-
scope (MTC-600, Bio-Rad, Hercules, CA, USA) was
used for image acquisition, and the deposition of brown
particles in the cytoplasm/nucleus indicated a positive
result. Cells displaying brown particles in the cyto-
plasm/nucleus were counted within the same sized area
as viewed under the microscope.
Western blot
An EpiQuik Nuclear Extraction Kit (Epigentek Group Inc,
New York, NY, USA) was used to extract total nuclear
protein from lung tissues and AT2 cells after exposure to
normoxia or hyperoxia, and AT2 cells after inhibitor
treatment. After SDS polyacrylamide gel electrophoresis
(SDS-PAGE), separated proteins were transferred onto
a polyvinylidene fluoride (PVDF) membrane, and the
membrane was then blocked with 10 % skimmed milk
and incubated overnight with various antibodies: (anti-
RUNX3, 1:800; anti-DNMT3B, 1:1000; anti-H3K27me3,
1:3000; anti-DNMT1, 1:200; anti-EZH2, 1:1000; anti-
GAPDH, 1:15,000 [all Santa Cruz Biotechnology]). The
membrane was then incubated in secondary antibody
for 4 h, washed in 10 mM Tris/HCl, 150 mM NaCl, and
0.05 % Tween 20, pH 7.5 (TBST) buffer three times,
developed with enhanced chemiluminescence substrate
(ECL kit; Santa Cruz Biotechnology) and exposed to
X-ray film. All bands on X-ray film were scanned using
ChemiImager 5500 V2.03 software. Integrated density
values were computed using an image analysis system
(Fluor Chen 2.0; Bio-Rad, Hercules, CA, USA) and
standardized to GAPDH.
Real-time PCR
Total mRNA was extracted from right upper lung lobe tis-
sues and AT2 cells after exposure to normoxia or hyper-
oxia, and from AT2 cells after inhibitor treatment. Briefly,
Trizol, chloroform and isopropyl alcohol were added and
samples subjected to reverse transcription and real-time
PCR (Life Technologies, Carlsbad, CA, USA) according to
kit instructions. Reverse transcription conditions were:
65 °C, 5 min; 37 °C, 2 min; 37 °C, 50 min; and 70 °C,
15 min. PCR conditions were 50 °C, 2 min; 95 °C, 2 min;
95 °C, 15 s; and 60 °C, 1 min for 40 cycles. Primer
sequences of different indicators are shown in Table 1,
and model data were standardized to GAPDH.
Bisulfite sequencing PCR (BSP)
After 7 and 14 days, the genomic DNA of AT2 cells in
model and control groups was extracted using a blood/
cell/tissue genomic DNA extraction kit (Tiangen Biotech,
Table 1 Real-time PCR primers for genes
Target gene 5′→ 3′ Product
dnmt1 Sense CATGGTGCTGAAGCTCACAC 176 bp
Antisense GGGCAAACACGTGTAGAGGT
dnmt3b Sense TTCTCATGATGCCAAAGCTC 118BP
Antisense GAGGTTCTTTGCCTCTCCAG
ezh2 Sense TTCGTTTTGCTAATCATTCAGTAA 162 bp
Antisense CCACATACTTCAGGGCATCA
runx3 Sense GAAGATAGAGGACCAGACCAAAG 194 bp
Antisense GGAAGGAGCGATCAAACTG
gapdh Sense AGACAGCCGCATCTTCTTGT 207 bp
Antisense CTTGCCGTGGGTAGAGTCAT
Table 2 CHIP-Real-time PCR primers for runx3
Gene locus 5′→ 3′ Product
1 Sense CTGTGGCTAAGAGGGTGAC 265 bp
Antisense ACAAGGCTGAAGATGACG
2 Sense TCTCCACCTCAGAACGC 192 bp
Antisense ACAAGGCTGAAGATGACG
3 Sense CGCATCCACTTCCACTACAC 180 bp
Antisense TTCCTGCCCACTCAAAA
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water, DNA was collected. Thereafter, DNA specimens
were treated with a DNA methylation kit (Millipore,
Billerica, MA, USA) and amplified. PCR amplification
conditions were 95 °C, 5 min; 95 °C, 10 s; 50 °C, 20 s; 72 °C,
30 s; 35 cycles; 4 °C, 5 min. Forward primer: 1: 5′-GG
ATTAAGGTTGAGAAGATGATGG-3′, reverse primer
1: 5′-ACCACCCTATTCCTACCCACTC-3′; forward
primer 2: 5′-TTAGAAGGGCGTTTAGGAGA-3′, re-
verse primer 2: 5′-AACTCTAACGATCCTCATCC-3′.
Amplicons were checked on agarose gel and sequenced
using BiQ Analyzer.
Chromatin Immunoprecipitation (ChIP) Assay
Chromatin co-immunoprecipitation was performed ac-
cording to manufacturer’s instructions (EZ-ChIP kit;
Millipore). In brief, 1 % (final concentration) formalde-
hyde was used to treat AT2 cells isolated from model
and control groups at 14 days; after protein-DNA cross-
linking, genomic DNA was ultrasonically sheared into
lengths of 200–1000 bp. Non-specific binding proteins
and DNA were pre-removed with Protein G agarose and
an antibody-free control sample was put aside. Normal
mouse IgG (IgG group), anti-H3K27me3 (target gene
group 1; 5 μL [Abcam]) or anti-EZH2 (target gene group
2; 2 μL [Millipore]) and Protein G agarose were added
to samples and incubated overnight. Samples were
washed according to instructions, eluted with elution
buffer to remove protein/DNA complexes, cross-linked,
purified step-by-step, and then amplified. Amplification
conditions were the same as for real-time PCR, and
primer sequences used are shown in Table 2. The model
results are expressed as 2-CT (Target gene group-Input group-
IgG group).
Statistical analysis
SPSS17.0 software (manufacture, city, country) was used
for statistical analysis. Inter-group comparisons were made
using t tests, multiple group comparisons made usingone-way analysis of variance (ANOVA), and correlation
analysis made using Pearson’s test. All data are presented
as mean (χ) ± standard deviation (SD). P < 0.05 suggests a
statistically significant difference.
Results
RUNX3 expression in lung tissues and AT2 cells following
hyperoxia
We studied RUNX3 protein localization by immunohis-
tochemical staining of lung tissues from both control
and BPD model groups exposed to hyperoxia over time;
RUNX3 protein expression was found in the nucleus
and cytoplasm of alveolar epithelial cells in lung sections
of both the control and model groups (Fig. 1a, b). We
also examined RUNX3 protein and mRNA levels in lung
tissue and AT2 cells isolated from these groups. Com-
pared with the control group, RUNX3 protein and
mRNA expression in lung tissues and AT2 cells from
the model group was significantly decreased by ≥ 7 days
of hyperoxia (Fig. 1; P < 0.05).
DNMT and histone methyltransferase EZH2 localization in
lung tissues following hyperoxia
The localization of DNMTs and EZH2 proteins in lung
tissues of animals exposed to hyperoxia or normoxia
was examined by immunohistochemistry. After 10 day
of hyperoxia, DNMT1 protein was expressed in both the
nucleus and cytoplasm of pulmonary epithelial cells in
the control group, but was poorly expressed in the
model group (Fig. 2a, b). In both the model and control
groups, DNMT3b protein was expressed in the nucleus
of alveolar epithelial and mesenchymal cells (Fig. 2c, d).
EZH2 protein was expressed in both the nucleus and
cytoplasm of alveolar epithelial cells in the model group,
but expression was greatly decreased in the control
group (Fig. 2e, f ).
DNMT expression levels in lung tissues and A2 cells
following hyperoxia
DNMTs protein levels in lung tissues of animals exposed
to hyperoxia or normoxia were also examined by Western
blot. Compared with the control group, DNMT1 protein
in lung tissues of the model group significantly increased
by ≥ 7 days, reached a peak at 10 day, and thereafter
Fig. 1 (See legend on next page.)
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Fig. 1 RUNX3 expression in lung tissues and AT2 cells following hyperoxia. RUNX3 protein localization in lung tissues by immunohistochemistry
showing RUNX3 protein expression in both the nucleus and cytoplasm of alveolar epithelial cells in control (a) and model groups (b). The arrow
indicates positive cells. (×400). Western blot of RUNX3 protein (c and d), and real-time PCR of RUNX3 mRNA (e) showing low expression in lung
tissues of the model group after 7 d hyperoxia. Low expression of RUNX3 protein (f and g) and mRNA (h) in AT2 cells from the model group after
7 d hyperoxia. C: Control group, E: model group, *P < 0.05 vs. control group, n = 4
Zhu et al. Respiratory Research  (2015) 16:75 Page 6 of 17decreased (Fig. 3a, b; P < 0.05), while DNMT3b protein
demonstrated a persistently high expression level after 7
days (Fig. 3a, c; P < 0.05). Subsequently, the expression of
DNMT1 and DNMT3b in AT2 cells extracted from lung
tissues was detected at different time points: Compared
with the control group, DNMT1 protein in AT2 cells iso-
lated from the model group rapidly decreased by ≥ 7 days,
and demonstrated a persistently and significantly low ex-
pression level (Fig. 3d, e; P < 0.05), while DNMT3b protein
increased by ≥ 10 day and demonstrated a significantly
high expression level (Fig. 3d, f; P < 0.05).
DNMTs mRNA levels in lung tissues and AT2 cells iso-
lated from animals exposed to hyperoxia or normoxia
were also examined by real-time PCR. In the model group,
DNMT1 mRNA was poorly expressed while DNMT3bFig. 2 DNMTs and EZH2 protein localization in lung tissues following hype
immunohistochemistry. After 10 day of hyperoxia, DNMT1 protein was exp
(a), but, in the model group, DNMT1 protein was barely detectable (b). In b
expressed in alveolar epithelial and mesenchymal cells. In the control grou
protein was expressed in alveolar epithelial cells (f). The arrow points to pomRNA was highly expressed in lung tissues after 10 day of
hyperoxia compared to the control group (Fig. 4a, b).
After 7 days of hyperoxia, DNMT1 mRNA was poorly
expressed in AT2 cells of hyperoxia group (Fig. 4c). For
both the model and control groups, DNMT3b mRNA was
equally expressed in AT2 cells after 1 day of hyperoxia
compared to the control group (Fig. 4d). DNMT1 and
DNMT3b mRNA levels in lung tissues and AT2 cells
showed similar changes to protein, but the differences be-
tween groups were not statistically significant (Fig. 4).
EZH2 expression levels in lung tissues and A2 cells
following hyperoxia
EZH2 protein levels in lung tissues and AT2 cells of
animals exposed to hyperoxia or normoxia were alsoroxia. DNMTs and EZH2 protein localization in lung tissues by
ressed in pulmonary alveolar epithelial cells in the control group
oth the control (c) and model groups (d), DNMT3b protein was
p, EZH2 protein was poorly expressed (e). In the model group, EZH2
sitive cells. (×400)
Fig. 3 DNMT protein levels in lung tissues and AT2 cells following hyperoxia. Western blot (a) showing DNMT1 protein was highly expressed in
lung tissues in the model group after between 7–10 day of hyperoxia, (b) and DNMT3b was highly expressed in the lower lobe of right lung
tissues after 7 days of hyperoxia (c). A Western blot of DNMT1 and DNMT3b protein expression in AT2 cells from lung tissue (d) showed DNMT1
protein was poorly expressed in AT2 cells from the model group after 7 days of hyperoxia (e) while DNMT3b protein was highly expressed in AT2
cells after 10 day of hyperoxia. (f). C: Control group, E: Model group, *P < 0.05 vs. control group, n = 4
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Fig. 4 DNMT mRNA levels in lung tissues and AT2 cells following hyperoxia. In the model group, DNMT1 mRNA, as determined by PCR, was
poorly (a) expressed while DNMT3b mRNA was highly expressed in lung tissues after 10 day of hyperoxia (b). After 7 days, DNMT1 mRNA was
poorly expressed in AT2 cells of model group (c). In both the model and control groups, DNMT3b mRNA was expressed in AT2 cells (d), but the
difference was not statistically significant after 7 days. *P < 0.05 vs. control group, n = 4
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group, EZH2 protein in lung tissues and AT2 cells in
the model group was significantly increased at ≥ 10 day of
hyperoxia (Fig. 5a, b; P < 0.05) and at ≥ 7 days (Fig. 5d, e;
P < 0.05), respectively. Real-time PCR results revealed that
EZH2 mRNA levels in lung tissues were persistently and
significantly high from 10 day onwards (Fig. 5c; P < 0.05),
while they were increased in AT2 cells at ≥ 7 days, but not
significantly (Fig. 5f).
Correlation between RUNX3 expression and DNMTs or EZH2
in AT2 cells
We next carried out correlation analyses between RUNX3
and DNMTs or EZH2 protein expression. DNMT1 proteinwas positively correlated with RUNX3 protein (Fig. 6a;
r1 = 0.415, P1 = 0.018), while DNMT3B and EZH2 both
showed a significant negative correlation with RUNX3
protein (Fig. 6b, c; r1 = −0.527, P1 = 0.002; r2 = −0.879,
P2 = 0.000, respectively).
DNA methylation in the RUNX3 promoter region
We also examined the promoter methylation of RUNX3
in AT2 cells. AT2 cells in both the control and model
groups were found to be in a high methylation state,
with the methylation proportion in the model group sig-
nificantly higher (Fig. 7; P < 0.05). However, compared
with the control group, the DNA methylation proportion
in the model group was not significantly different at 7
Fig. 5 EZH2 protein and mRNA levels in lung tissues and AT2 cells following hyperoxia. In the model group, EZH2 protein, as determined by
Western blot, (a and b) and mRNA, as determined by real time-PCR (c), were highly expressed in lung tissues after 10 day of hyperoxia, while
EZH2 protein (d and e) and mRNA (f) were highly expressed in AT2 cells after 7 days of hyperoxia. C: Control group, E: Model group, *P < 0.05 vs.
control group, n = 4
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days (Fig. 7). Thus the RUNX3 promoter of AT2 cells
derived from the model group under hyperoxia showed
hypermethylation compared to that of the control group.Binding between H3K27me3/EZH2 and the RUNX3 promoter
We also examined binding between H3K27me3 or
EZH2 and the RUNX3 promoter in AT2 cells from
control and model groups. Compared with the control
Fig. 6 Analysis of the correlation between RUNX3 and DNMTs or
EZH2 protein expression in AT2 cells. RUNX3 protein expression
correlated positively with DNMT1 protein expression (a), but negatively
with DNMT3b (b) and EZH2 (c) protein expression in AT2 cells.
*P < 0.05, n = 4
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sequence 2 (−5407 ~ −5215 bp) both significantly bound
to H3K27me3 or EZH2 at high levels in the BPD model
group at 14 days (Fig. 8a, b; P < 0.05); binding between
RUNX3 sequence 2 and H3K27me3 was more signifi-
cant (P < 0.05). The binding level of RUNX3 sequence 3
(−571 ~ −391 bp) with EZH2 was also significantly
higher (Fig. 8a, b; P < 0.05), but that with H3K27me3
was not significantly different in the BPD model group
compared to control. Thus binding occurs between the
RUNX3 promoter and H3K27me3 or EZH2 in AT2 cells
of the BPD model group. This suggests EZH2-mediated
H3K27 methylation occurs at the RUNX3 promoter
under hyperoxia.
RUNX3 protein and mRNA expression over time in AT2
cells following hyperoxia
We analyzed the expression of RUNX3 protein and
mRNA over time in AT2 cells derived from control and
model cells. Compared with the control group, RUNX3
protein and mRNA expression in AT2 cells from the
model group cultured in an 85 % O2 environment sig-
nificantly decreased by 48–72 h (Fig. 9a; P < 0.05). These
results suggest that RUNX3 expression is inhibited by
hyperoxia.
Effects of inhibitor treatment on RUNX3 protein and
mRNA expression in AT2 cells
We next analyzed the effects of the inhibition of methy-
lation on RUNX3 protein and mRNA levels in AT2 cells
derived from control and model cells. When compared
with the control group, RUNX3 protein levels in AT2 cells
from the model group were significantly up-regulated at
48 h after treatment with JMJD3, a H3K27 demethylase,
or DZNep, an EZH2 inhibitor, but not with the DNA
methylation inhibitor, 5-Aza-CdR (Fig. 9b; P < 0.05).
However, RUNX3 protein and mRNA levels were mark-
edly, and significantly, up-regulated after 72 h treatment
with all three inhibitors (Fig. 9b, c; P < 0.05). These re-
sults suggest that DNMT-mediated DNA methylation
and H3K27me3 both induce RUNX3 protein down-
regulation after 72 h.
AT2 cells were then treated with different concentra-
tions of inhibitors for 48 h. Compared with untreated
cells, 2.5 μmol/L 5-Aza-CdR (Fig. 10a, b, c) and 1 μmol/L
DZNep (Fig. 10d, e, f ) both significantly up-regulated
RUNX3 protein and mRNA in AT2 cells from the control
group (P < 0.05 for both), while 10 μg/L JMJD3 caused no
Fig. 7 BSP detection of DNA methylation in the RUNX3 promoter region of AT2 cells. The detection of 16 sites in the RUNX3 promoter region by
BSP demonstrated the DNA methylation percentage of the RUNX3 promoter region in AT2 cells (a). In each specimen, the DNA methylation
proportion differed at different sites (b, c). The DNA methylation proportion was higher in AT2 cells of the model group compared to that in the
control group (d). Closed circles: methylated CpGs; open circles: unmethylated CpGs. *P < 0.05 vs. control group, n = 7
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2.5 μmol/L 5-Aza-CdR (Fig. 10a, b, c), 1 μmol/L DZNep
(Fig. 10d, e, f ) and 10 μg/L JMJD3 (Fig. 10g, h, i) all signifi-
cantly up-regulated RUNX3 protein and mRNA in AT2cells from the model group (Fig. 10; P < 0.05). These re-
sults suggest that the inhibition of histone or DNA
methylation upregulates RUNX3 expression in a dose-
dependent manner.
Fig. 8 Binding between H3K27me3/EZH2 and the RUNX3 promoter in AT2 cells. As determined by ChIP, binding levels between H3K27me3 (a) or
EZH2 (b) and the RUNX3 promoter region were higher in AT2 cells after 14 days of hyperoxia compared to the control group. Gene locus 1: RUNX3
promoter region −5407 ~ −5142 bp; 2: RUNX3 promoter region −5407 ~ −5215 bp; 3: RUNX3 promoter region −5407 ~ −5142 bp. *P < 0.05 vs. control
group, n = 10
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BPD is an infantile disease, frequently seen in premature
infants of low fetal age and birth weight, with a compli-
cated pathogenesis. We have previously found that new-
born BPD rat lung tissues displayed enlarged alveolar
spaces, thickened pulmonary septa, increased alveoli
number and secondary septa, a simplified alveolar struc-
ture, and a persistently low RAC (a pulmonary develop-
ment evaluation index), all which indicate a pulmonary
developmental disorder [4, 26].
RUNX3, a member of the RUNX family, is a gene asso-
ciated with pulmonary development. At E17.5, RUNX3
protein was widely distributed in bronchioles and alveolar
epithelial cells of mouse lung tissues, and participated in
the differentiation of pulmonary epithelial cells [8] and the
formation of pulmonary blood vessels [7]. RUNX3 knock-
out mice displayed lethal, excessive proliferation and
abnormal differentiation of cells, 24 h after birth [8]. In
this study, we found RUNX3 expression in alveolar epithe-
lial cells that was significantly decreased in newborn rats
and AT2 cells, 7 days and 48 h, respectively, after hyper-
oxia induction; noted pathological changes were similar to
those in RUNX3 knock-out mice. This suggests that
RUNX3 down-regulation in the late stages of hyperoxia
may cause excessive proliferation and abnormal differenti-
ation of AT2 cells, and thus contribute to the occurrence
of pulmonary developmental disorder in BPD.
In recent years, numerous studies have suggested that
BPD is a genetically susceptible disease, to which both
environment and genetics jointly contribute [1]. For
instance, the BPD status of one twin was found to be asignificant predictor of BPD in the second twin, with a
higher incidence noted in homozygotic twins [18, 19].
Epigenetics is a post-transcriptional or post-translational
modification mechanism that does not require a change
of gene sequence or genetic transmission to the next
generation by cell division [28]; an example is the intra-
uterine or postpartum environment causing DNA methy-
lation, making infants susceptible to chronic obstructive
pulmonary disease, asthma and other respiratory system
diseases [9, 29]. Does hyperoxia-induced BPD also involve
an epigenetic mechanism, notably, commonly occurring
DNA or histone methylation? In this study, we found
the increased expression of the DNA methylation
modification enzymes, DNMT1 and DNMT3b, and the
H3K27me3 modification enzyme, EZH2, in lung tissues
of the BPD model group from 7 and 10 day, respect-
ively, with similar results in AT2 cells. These findings
indicate that DNA methylation and H3K27me3 modifi-
cation may exist in BPD.
Many studies have reported that RUNX3 is a CpG island
methylation phenotype, rich in CG sites [29]. RUNX3
often regulates expression at the post-transcriptional level
by DNA methylation between the 5′-terminal and TSS of
genes [9]. Considering the possible presence of DNA
methylation in BPD, we hypothesized that the down-
regulated expression of pulmonary development-related
genes such as RUNX3 in BPD could be associated with
such a modification mechanism. We therefore analyzed
correlations between RUNX3 protein and DNMT ex-
pression in AT2 cells. DNMT1 protein was only highly
expressed after 1 day of hyperoxia, while DNMT3b
Fig. 9 (See legend on next page.)
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Fig. 9 RUNX3 protein and mRNA levels over time in AT2 cells after inhibitor treatment. RUNX3 protein expression in AT2 cells was detected by
Western blot at different time points after JMJD3 (20 μg/L), DZNep (1 μmol/L) or 5-Aza-CdR (5 μmol/L) treatment (a). In the model group, RUNX3
protein in AT2 cells was up-regulated after 48 h with JMJD3 or DZNep, but not 5-Aza-CdR, treatment (b). As detected by real-time PCR, RUNX3
mRNA in AT2 cells of the model group was up-regulated after 72 h treatment with JMJD3, DZNep or 5-Aza-Cd (c). 24, 48, 72 h: 24, 48 and 72 h
after inhibitor treatment. *P < 0.05 vs. control group; #P < 0.05 vs. model group, n = 4
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10 day of hyperoxia onwards, and markedly and
negatively correlated with RUNX3 protein. We there-
fore inferred that RUNX3 down-regulation in AT2
cells may be related to DNA methylation mechanisms
in BPD.Fig. 10 RUNX3 protein and mRNA levels in AT2 cells after 48 h treatment
model groups were treated with various inhibitors. As detected by Western
model groups increased after 48 h treatment with different concentrations
5 μmol/L) or JMJD3 (g and h, 10, 20, 40 μg/L). As detected by real-time PC
groups increased after 48 h treatment with different concentrations of 5-Az
vs. model group, n = 4DNA methylation involves the transfer of a methyl
group from S-adenosylmethionine to cytosine on two
CG nucleotides of DNA to form 5-methylcytosine;
DNMTs catalyze this reaction, which leads to the silen-
cing of gene expression [15, 16]. Using BSP, we found
that in both the model and control groups, the RUNX3with different concentrations of inhibitors. Cells from control and
blot, RUNX3 protein expression in AT2 cells from both control and
of 5-Aza-CdR (a and b, 2.5, 5, 10 μmol/L), DZNep (d and e, 1, 2.5,
R, RUNX3 mRNA expression in AT2 cells from both control and model
a-CdR (c), DZNep (f) or Jmjd3 (i). *P < 0.05 vs. control group; #P < 0.05
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of DNA methylation after between 7–14 days of hyper-
oxia, with a greater proportion in the model group after
14 days of hyperoxia. We therefore speculated that DNA
methylation may contribute to RUNX3 down-regulation
in the late stages of BPD. Although we unexpectedly
found a high incidence of methylation in the control
group, especially 7 days after hyperoxia, this incidence
was lower than that in the model group, with no signifi-
cant difference between the two groups.
Most tumor studies show a low probability of RUNX3
DNA methylation in normal tissue specimens [30], so
the observation that RUNX3 in newborn rat lung tissues
displayed differential DNA methylation at different inter-
vals after birth is puzzling. Scholars have found that a
very low concentration of oxygen can change DNMT ac-
tivity in DNA injury [31]. In the early stages after birth,
newborn rats are transferred to a postpartum hyperoxic
environment from an intrauterine hypoxic environment
[32], so their lung tissues are stimulated by relative
hyperoxia. We postulated that DNA methylation in the
control group was attributable to a change in DNMT
activity caused by the transient stimulation of relative
hyperoxia after birth; however this hypothesis has yet to
be tested.
Common DNMTs include DNMT1, which maintains
and regulates DNA methylation, and DNMT3a/b, which
establishes de novo methylation [15, 16]. It was thought
that the major contributor of RUNX3 DNA methylation
was DNMT1; however when DNMT1 siRNA inhibited
target cells, RUNX3 expression partially recovered, which
was not observed after DNMT3b inhibition [17]. DNMT3b
is thought to be a key enzyme in the regulation of gene
methylation. Deng et al. [10] treated a colorectal cancer cell
line with 5-Aza-CdR and found that DNMT3b, but not
DNMT1, expression was inhibited, causing upregulated
RUNX3 expression. Similarly, in this study, we observed
DNMT3b expression in AT2 cells was negatively related to
RUNX3 protein expression. RUNX3 expression in AT2
cells was up-regulated after inhibition using different
concentrations of 5-Aza-CdR over time. We therefore
inferred that DNMT3b played a dominant role in the
DNA methylation of the RUNX3 promoter.
However, others have proposed that the silencing of
RUNX3 expression is associated with EZH2-mediated
H3K27me3 modification [10]. This involves the amino
terminal of the histone binding to a specific modification
group under the action of the methyltransferase, EZH2
[11], and demethyltransferase, JMJD3/UTX [12], to
reduce transcription [13]. Hence, H3K27me3 is a stable,
inhibitory chromatin marker. H3K27me3 protects and
maintains cell totipotency by inhibiting the expression of
regulatory genes in embryonic stem cells [33]. AT2 cells
are similar to stem cells, and can differentiate into AT1cells in the late stages of embryonic development [34],
and into myofibroblasts in the late stages of epithelial-
mesenchymal transition (EMT) [35]. This study showed
that, in either lung tissues or extracted AT2 cells, the
expression of EZH2 in the BPD model group was signifi-
cantly higher than that in the control group, and was
negatively correlated to RUNX3 protein. Therefore, we
postulated that in the intrauterine development phase
and the postpartum, abnormal differentiation process of
BPD, RUNX3 down-regulation may be related to EZH2-
mediated H3K27me3 modification.
Fujii et al. [14] found that EZH2 knock-out reduced
H3K27me3-binding RUNX3 levels and thus up-regulated
RUNX3 mRNA levels; they believed RUNX3 silencing was
a result of EZH2-dependent H3K27me3 modification.
In this study, using a ChIP technique, we detected
H3K27me3-binding and EZH2-binding RUNX3 levels
in AT2 cells extracted from lung tissues of the model
and control groups at 14 days, with higher levels found
in the model group. The −5407 ~ −5215 sequence in
the promoter region tightly bound to H3K27me3, while
the sequence between −5407 ~ −5142 and −571 ~ −391
tightly bound to EZH2. We therefore believe EZH2-
mediated H3K27 trimethylation may also be involved in
RUNX3 down-regulation in our BPD model.
We found that the downregulation of RUNX3 expres-
sion in the late stages of BPD may be due to DNA
methylation and H3K27me3 modification. In order to
verify this, we treated AT2 cells with inhibitors over
time: d5-Aza-CdR, a DNMT inhibitor [36]; JMJD3, an
H3K27me3 demethyltransferase that antagonizes EZH2
[37]; and DZNep, which inhibits EZH2 [38]. We detected
RUNX3 expression in AT2 cells after inhibitor treatment
by Western blot and real-time PCR. We found that by
48 h, 5-Aza-CdR, Jmjd3 and DZNep significantly up-
regulated RUNX3 protein and mRNA which suggests that
DNMT3b-mediated DNA methylation and H3K27me3
both participate in RUNX3 protein down-regulation
during the late stages of hyperoxia-induced BPD.
How do DNA or histone methylation play dominant
roles in RUNX3 down-regulation? Researchers found
EZH2 knock-out increased RUNX3 mRNA levels 3.5–
10.4-fold, an effect markedly stronger than that of DNA
methylation inhibitors; they therefore inferred that
histone modification was a dominant mechanism [14].
However, Liudmila et al. [39] questioned this conclusion,
after observing that EZH2 knock-out alone did not
recover gene expression, and that RUNX3 expression
recovered after pre-treatment with DNA methylation
inhibitors. We found that compared with the model
group at the same time points, RUNX3 protein and
mRNA levels in the control group were both signifi-
cantly up-regulated at 48 h after treatment with the his-
tone methylation inhibitor, JMJD3, or EZH2 inhibitor,
Zhu et al. Respiratory Research  (2015) 16:75 Page 16 of 17DZNep; the effect of the DNA methylation inhibitor,
5-Aza-CdR, was less significant, with a change only
observed after 72 h. Therefore, we believe that during
RUNX3 protein down-regulation in the late stages of
hyperoxia-induced BPD, EZH2-mediated H3K27me3
plays a dominant role to that of DNMT3b-mediated
methylation.
Conclusions
In conclusion, this study confirms not only the co-
presence of two epigenetic modification mechanisms–
DNA methylation and H3K27me3–in a newborn rat
model of hyperoxia-induced BPD, but also the joint
contribution of DNMT3b-mediated DNA methylation
and EZH2-mediated H3K27me3 to RUNX3 protein
down-regulation in the late stages of BPD. This suggests
that, by early screening and treatment with epigenetic
modification mechanisms, we can hope to minimize
damage induced by environmental and genetic factors
to premature infants and the risk of lung diseases like
BPD occurring in the future.
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